{
    "Trade/Device Name(s)": [
        "cobas c Bilirubin Total Gen.3",
        "Bilirubin Total Gen.3"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K131544",
    "Predicate Device Reference 510(k) Number(s)": [
        "K063543"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG",
        "MQM"
    ],
    "Summary Letter Date": "March 14, 2019",
    "Summary Letter Received Date": "May 29, 2013",
    "Submission Date": "May 28, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Gel Separation Tube",
        "Li-heparin tube",
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "cobas c 501 analyzer",
        "cobas e 501 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Diazo colorimetric method",
        "Photometric determination"
    ],
    "Methodologies": [
        "Colorimetric quantification"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Roche cobas c Bilirubin Total Gen.3, a quantitative in vitro diagnostic reagent for total bilirubin in serum and plasma using diazo colorimetric method on Roche/Hitachi cobas c analyzers.",
    "Indications for Use Summary": "In vitro test for the quantitative determination of total bilirubin in serum and plasma of adults and neonates on Roche/Hitachi cobas c systems; aids in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and gall bladder block.",
    "fda_folder": "Clinical Chemistry"
}